Cholesterol Medication Recall Upgraded to Higher Risk Level
A recall of nearly 142,000 bottles of Atorvastatin Calcium Tablets, used to lower cholesterol, has been elevated to a Class II recall by the U.S. Food and Drug Administration, indicating a potential for temporary or reversible health consequences.
The FDA initially announced the recall by Ascend Laboratories in September due to “failed dissolution specifications,” meaning the tablets did not dissolve as expected during testing. The recall affects 90-count, 500-count, and 1,000-count bottles with expiration dates up to February 2027, and was distributed nationwide. Specific lot numbers can be found on the FDA website. When a medication fails to dissolve properly, the FDA explains, it may not be effectively absorbed by the body.
While no illnesses have been reported to date, this recall impacts a significant number of Americans, as approximately 47 million Americans take cholesterol medication daily to manage heart health. Statins like Atorvastatin are crucial in preventing heart attack and stroke by reducing cholesterol buildup in arteries. This recall highlights the importance of rigorous quality control in pharmaceutical manufacturing.
The FDA stated that a Class II recall is issued when the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or when the probability of serious adverse health consequences is remote. Officials will continue to monitor the situation and provide updates as needed.
